<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119236</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01467</org_study_id>
    <secondary_id>05-017</secondary_id>
    <secondary_id>MSKCC-IRB-05017</secondary_id>
    <secondary_id>NCI-7009</secondary_id>
    <secondary_id>CDR0000434501</secondary_id>
    <secondary_id>U01CA069856</secondary_id>
    <nct_id>NCT00119236</nct_id>
  </id_info>
  <brief_title>17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>An Open-Labeled Non-Randomized Phase I Study of 17-N-allylamino-17-demethoxy Geldanamycin (17AAG) Administered With Irinotecan (CPT-11) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of 17-AAG and irinotecan in&#xD;
      treating patients with locally advanced or metastatic solid tumors. Drugs used in&#xD;
      chemotherapy, such as 17-AAG and irinotecan, work in different ways to stop the growth of&#xD;
      tumor cells either by killing the cells or by stopping them from dividing. Giving more than&#xD;
      one drug (combination chemotherapy) may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the maximum tolerated dose (MTD) of combined 17AAG and irinotecan given&#xD;
      weekly for two weeks in a 21-day cycle that can be used for future phase II studies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the effects of the combination on the expression of Hsp90 client proteins in&#xD;
      peripheral mononuclear cells and tumor tissues. Tumor biopsies will be performed before and&#xD;
      after 17AAG treatment in 12 patients at the MTD (&quot;Expanded Cohort&quot;) only.&#xD;
&#xD;
      II. To investigate the clinical pharmacokinetics of intravenous 17AAG, irinotecan, and their&#xD;
      metabolites, in this combination.&#xD;
&#xD;
      III. To obtain preliminary data on the therapeutic activity of 17AAG in combination with&#xD;
      irinotecan in patients with advanced solid tumors.&#xD;
&#xD;
      IV. To obtain preliminary result in the relationship between tumor response and p53-status.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, dose-escalation study.&#xD;
&#xD;
      Patients receive irinotecan IV over 30 minutes followed by&#xD;
      17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment&#xD;
      repeats every 21 days for at least 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients achieving stable or improved disease after course 2 may&#xD;
      receive additional courses of treatment.&#xD;
&#xD;
      NOTE: *17-AAG is administered on days 2 and 8 during course 2 for patients treated at&#xD;
      non-maximum tolerated doses (MTD) (dose-escalation portion) and on day 8 only during course 1&#xD;
      for patients treated at the MTD (expanded cohort).Cohorts of 3-6 patients receive escalating&#xD;
      doses of 17-AAG and irinotecan until the MTD is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An&#xD;
      additional 12 patients are treated at the MTD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose determined by dose-limiting toxicities</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>17-AAG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor, excluding primary CNS tumors&#xD;
&#xD;
               -  Locally advanced or metastatic disease that is refractory to standard therapy OR&#xD;
                  for which no standard therapy exists&#xD;
&#xD;
          -  Tumor assessible for biopsy by Tru-cut^®, CT guidance, or endoscopy (for patients&#xD;
             treated at the maximum tolerated dose [expanded cohort only])&#xD;
&#xD;
               -  Pleural effusions or abdominal ascites are not considered biopsy-accessible&#xD;
                  tissue&#xD;
&#xD;
          -  No known new CNS metastases that have not been previously treated&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are&#xD;
             present)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  No history of cardiac arrhythmias&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No active ischemic heart disease within the past 12 months&#xD;
&#xD;
          -  No New York Heart Association class III-IV congestive heart failure or LVEF &lt; 40% by&#xD;
             MUGA&#xD;
&#xD;
          -  No history of uncontrolled cardiac dysrhythmia or dysrhthmias requiring medication&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
             ventricular fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
          -  QTc &lt; 450 msec (for male patients)&#xD;
&#xD;
          -  QTc &lt; 470 msec (for female patients)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No nursing during and for 2 months after study participation&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
          -  No serious or uncontrolled infection&#xD;
&#xD;
          -  No history of serious allergic reaction to eggs or egg products&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  At least 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  Prior irinotecan allowed&#xD;
&#xD;
          -  No prior 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)&#xD;
&#xD;
          -  At least 2 weeks since prior non-myelosuppressive chemotherapy (at the discretion of&#xD;
             the principal investigator)&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy field that included the heart (e.g., mantle)&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 3 weeks since prior anticancer investigational therapeutic drugs&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent inducers, inhibitors, or modifiers of&#xD;
             CYP3A4, including any of the following:&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Azithromycin&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Nifedipine&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Nefazodone&#xD;
&#xD;
               -  Cyclosporine&#xD;
&#xD;
               -  Grapefruit juice (&gt; 1 quart/day)&#xD;
&#xD;
               -  Indinavir&#xD;
&#xD;
               -  Nelfinavir&#xD;
&#xD;
               -  Ritonavir&#xD;
&#xD;
               -  Saquinavir&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Hydrastis canadensis (goldenseal)&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Uncaria tomentosa (cat's claw)&#xD;
&#xD;
               -  Echinacea angustifolia root&#xD;
&#xD;
               -  Trifolium pratense (wild cherry)&#xD;
&#xD;
               -  Matricaria chamomila (chamomile)&#xD;
&#xD;
               -  Glycyrrhiza glabra (licorice)&#xD;
&#xD;
               -  Dillapiol&#xD;
&#xD;
               -  Hypericin&#xD;
&#xD;
               -  Naringenin&#xD;
&#xD;
          -  No concurrent medications that would prolong QTc&#xD;
&#xD;
          -  No concurrent vitamins, antioxidants, herbal preparations, or supplements&#xD;
&#xD;
               -  Concurrent single daily multivitamin allowed&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Archie Tse</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

